Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026
Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026
Company Deals

Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China

Fineline Cube Nov 15, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...

Company Deals

Sansure Biotech Partners with UBC to Manufacture in Indonesia

Fineline Cube Nov 15, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...

Company

HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals

Fineline Cube Nov 15, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...

Company Deals

Harbour BioMed and WuXi Biologics Announce Strategic Collaboration

Fineline Cube Nov 15, 2022

Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...

Company Drug

Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...

Policy / Regulatory

CDE Issues Guidelines for Bispecific Antibody Antitumor Drug Development

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company Drug

AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval

Fineline Cube Nov 14, 2022

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...

Company Drug

Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations

Fineline Cube Nov 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...

Company

CStone Launches Patient Assistance Program for IDH1 Inhibitor Tibsovo

Fineline Cube Nov 14, 2022

CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support...

Company Drug

HutchMed Announces Initial Results from FRUTIGA Phase III Study

Fineline Cube Nov 14, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...

Company Deals

BRL Medicine Raises RMB 200M in Series B Financing for CGT Development

Fineline Cube Nov 14, 2022

BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly...

Company Medical Device

Peijia Medical Enrolls First Patient in HighLife TSMVR Study

Fineline Cube Nov 14, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the enrollment of the first patient and...

Company Medical Device

Acotec Scientific Secures FDA 510(k) Approval for Vericor Catheter

Fineline Cube Nov 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received a 510(k)...

Company

CStone Pharmaceuticals Suspends Operations at Suzhou Plant to Cut Costs

Fineline Cube Nov 14, 2022

CStone Pharmaceuticals (HKG: 2616) has decided to suspend manufacturing operations at its Suzhou industrialization plant,...

Company Deals

Daxiang Biotech Raises RMB 100M in Pre-Series B Financing for Organoid-on-a-Chip

Fineline Cube Nov 14, 2022

Beijing-based Daxiang Biotech Co., Ltd., a leading domestic company in the organoid-on-a-chip field, has reportedly...

Company

Harbin Gloria Pharmaceuticals Faces Change in Control Amid Bankruptcy

Fineline Cube Nov 14, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has disclosed that its controlling shareholder, Harbin...

Company Deals

HitGen Partners with Daewoong Pharmaceutical for Drug Discovery

Fineline Cube Nov 14, 2022

China-based HitGen Inc. (SHA: 688222) has announced a research collaboration agreement with South Korea’s Daewoong...

Deals

AstraZeneca and CICC Capital Launch RMB 3 Billion Fund in Hangzhou

Fineline Cube Nov 14, 2022

The joint venture (JV) between UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CICC...

Company Drug

Henlius Biotech’s BRAF V600E Inhibitor HLX208 Approved for Clinical Study in China

Fineline Cube Nov 14, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

China Updates Hypertension Guidelines, Lowers Diagnostic Threshold

Fineline Cube Nov 14, 2022

The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...

Posts pagination

1 … 542 543 544 … 607

Recent updates

  • Biocytogen Licenses ADC Programs to Acepodia in Option Deal
  • Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO
  • Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.